Clinacanthus nutans (Burm.f.) Lindau facilitates cuproptosis and ameliorates colon cancer progression by inhibiting PDE3B-mediated Apelin pathway
Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-canc...
Saved in:
Published in | Discover. Oncology Vol. 16; no. 1; pp. 1521 - 15 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer US
11.08.2025
Springer Nature B.V Springer |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and
Clinacanthus nutans
(Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.
Methods
A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.
Results
CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.
Conclusion
Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.
Highlights
CN exerts anti-tumor effect in colon cancer.
CN delays tumorigenesis through suppressing PDE3B.
PDE3B silencing enhances cuproptosis in CN-treated cells.
CN attenuates colon cancer by modulating PDE3B through via the Apelin pathway. |
---|---|
AbstractList | Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.BACKGROUNDColon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.METHODSA BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.RESULTSCN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.CONCLUSIONOur study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer. Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer. A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells. CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway. Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer. CN exerts anti-tumor effect in colon cancer. CN delays tumorigenesis through suppressing PDE3B. PDE3B silencing enhances cuproptosis in CN-treated cells. CN attenuates colon cancer by modulating PDE3B through via the Apelin pathway. Abstract Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer. Methods A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells. Results CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway. Conclusion Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer. BackgroundColon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.MethodsA BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.ResultsCN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.ConclusionOur study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.HighlightsCN exerts anti-tumor effect in colon cancer.CN delays tumorigenesis through suppressing PDE3B.PDE3B silencing enhances cuproptosis in CN-treated cells.CN attenuates colon cancer by modulating PDE3B through via the Apelin pathway. Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer. Methods A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells. Results CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway. Conclusion Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer. Highlights CN exerts anti-tumor effect in colon cancer. CN delays tumorigenesis through suppressing PDE3B. PDE3B silencing enhances cuproptosis in CN-treated cells. CN attenuates colon cancer by modulating PDE3B through via the Apelin pathway. |
ArticleNumber | 1521 |
Author | Lin, Xueying Chen, Xuewu Zhou, Gaoyun Su, Dewen Lai, Zhiheng Lin, Long |
Author_xml | – sequence: 1 givenname: Gaoyun surname: Zhou fullname: Zhou, Gaoyun organization: Department of Surgery I, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital – sequence: 2 givenname: Xueying surname: Lin fullname: Lin, Xueying organization: Department of Oncology Intervention, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital – sequence: 3 givenname: Zhiheng surname: Lai fullname: Lai, Zhiheng organization: Department of Proctology, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital – sequence: 4 givenname: Dewen surname: Su fullname: Su, Dewen organization: Department of Surgery I, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital – sequence: 5 givenname: Long surname: Lin fullname: Lin, Long email: 13907629038@163.com organization: Department of Surgery I, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital – sequence: 6 givenname: Xuewu surname: Chen fullname: Chen, Xuewu email: dahei_858812@163.com organization: Department of Oncology Intervention, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40788438$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1u1DAQgCNUREvpC3BAlriUQxY7dhL7hNqlQKWV4ABna9Y_Wa-ydrATVvsYvDFmU0rLgYNly_PN55-Z58WJD94UxUuCFwTj9m0iVdNWJa7qPDBty_2T4qxqKS4bTMjJg_VpcZHSFuOMEkpx_aw4ZbjlnFF-Vvxc9s6DAj9upoT8NIJP6PJ6iruFXbxBK-c1TMiCcr0bYTQJqWmIYRhDcgmB1wh2pnchzrHQB4-yTZmIMtZFk5LLW-sDcn7j1m50vkNf3t_Q63JntMtZGl0N2eDRAONmD4cXxVMLfTIXd_N58e3Dzdflp3L1-ePt8mpVKobFvtTaCA2a1LjmTDBe25rA2jLMG1xR0bbYNlwJYRstMFWCGhC8YtQKY1uwLT0vbmevDrCVQ3Q7iAcZwMnjRoidhDg61RvJoeUKsgETzgjRorYNazjjhGBLlc6ud7NrmNb5Wcr4MUL_SPo44t1GduGHJBWlgtMmGy7vDDF8n0wa5c4lZfoevAlTkrSiuWBVw2hGX_-DbsMUff6rI1VXosYsU68eXun-Ln9Kn4FqBlQMKUVj7xGC5e8Wk3OLydw38thicp-T6JyUMuw7E_-e_Z-sXxc71PU |
Cites_doi | 10.1038/s41598-018-32267-8 10.1093/abbs/gmab134 10.1186/s12951-024-02480-x 10.1158/1541-7786.MCR-18-0989 10.1002/tox.22629 10.1158/1541-7786.MCR-20-0991 10.1007/s12079-023-00779-2 10.1007/s00268-021-06188-z 10.1016/j.intimp.2017.01.013 10.3748/wjg.v29.i4.670 10.1038/s41434-020-0167-3 10.1016/j.prp.2020.153247 10.3390/cimb45100536 10.1007/s00210-023-02928-1 10.21873/anticanres.14760 10.1016/j.carbpol.2015.10.102 10.1158/1078-0432.CCR-18-0815 10.2174/0115665232273077240104045022 10.3390/ijms241310789 10.3390/ijms231810600 10.1016/j.ejphar.2021.174464 10.7555/JBR.34.20200021 10.1186/s12906-019-2663-9 10.1007/s11356-022-20858-y 10.1080/13880209.2017.1288749 10.1002/ptr.7521 10.1080/01635581.2021.2014901 10.3389/fphar.2024.1290592 10.1371/journal.pone.0256012 10.1016/j.jnutbio.2024.109623 10.1002/jbt.23525 10.1177/00368504211011341 |
ContentType | Journal Article |
Copyright | The Author(s) 2025 2025. The Author(s). The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
DBID | C6C AAYXX CITATION NPM 3V. 7RV 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S NAPCQ PHGZM PHGZT PIMPY PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1007/s12672-025-02037-w |
DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2730-6011 |
EndPage | 15 |
ExternalDocumentID | oai_doaj_org_article_8a78ca3ea018411d95f646848110f3cd PMC12339836 40788438 10_1007_s12672_025_02037_w |
Genre | Journal Article |
GeographicLocations | Beijing China United States--US China Shenzhen China Shanghai China |
GeographicLocations_xml | – name: Shenzhen China – name: China – name: Shanghai China – name: Beijing China – name: United States--US |
GroupedDBID | 0R~ 2JY 53G 7RV 7X7 8FI 8FJ AAJSJ AASML ABUWG AFBBN AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR C6C CCPQU EBS FYUFA GROUPED_DOAJ HMCUK NAPCQ PGMZT PHGZM PHGZT PIMPY PPXIY RPM SOJ UKHRP AAYXX CITATION NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c409w-dde9dad1505849485f51abf40860239770f68c99f6d903c93ea98243f9ef7af73 |
IEDL.DBID | DOA |
ISSN | 2730-6011 |
IngestDate | Wed Aug 27 01:31:51 EDT 2025 Thu Aug 21 18:28:13 EDT 2025 Mon Aug 11 17:31:14 EDT 2025 Sat Aug 23 12:22:00 EDT 2025 Fri Aug 15 02:01:21 EDT 2025 Thu Aug 21 00:12:33 EDT 2025 Tue Aug 12 01:10:43 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Apelin pathway (Burm.f.) Lindau Colon cancer Cuproptosis PDE3B Clinacanthus nutans (Burm.f.) Lindau |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c409w-dde9dad1505849485f51abf40860239770f68c99f6d903c93ea98243f9ef7af73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://doaj.org/article/8a78ca3ea018411d95f646848110f3cd |
PMID | 40788438 |
PQID | 3238529504 |
PQPubID | 5642930 |
PageCount | 15 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8a78ca3ea018411d95f646848110f3cd pubmedcentral_primary_oai_pubmedcentral_nih_gov_12339836 proquest_miscellaneous_3238432643 proquest_journals_3238529504 pubmed_primary_40788438 crossref_primary_10_1007_s12672_025_02037_w springer_journals_10_1007_s12672_025_02037_w |
PublicationCentury | 2000 |
PublicationDate | 20250811 |
PublicationDateYYYYMMDD | 2025-08-11 |
PublicationDate_xml | – month: 8 year: 2025 text: 20250811 day: 11 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: United States |
PublicationTitle | Discover. Oncology |
PublicationTitleAbbrev | Discov Onc |
PublicationTitleAlternate | Discov Oncol |
PublicationYear | 2025 |
Publisher | Springer US Springer Nature B.V Springer |
Publisher_xml | – name: Springer US – name: Springer Nature B.V – name: Springer |
References | IN Zulkipli (2037_CR40) 2017; 55 KM Abdullah (2037_CR13) 2024; 10 Z Sun (2037_CR28) 2020; 35 M Rahimpour (2037_CR21) 2022; 74 Y Feng (2037_CR34) 2024 FJ Nordin (2037_CR10) 2021; 16 OP Pulkka (2037_CR19) 2019; 25 NZ Ismail (2037_CR27) 2022; 29 L Wei (2037_CR30) 2022; 29 Y Ruan (2037_CR14) 2024; 13 CM Lin (2037_CR7) 2023; 24 Q Feng (2037_CR12) 2024; 15 D Neelakantan (2037_CR37) 2019; 17 V Karpisheh (2037_CR23) 2020; 216 SN Jia (2037_CR1) 2022; 86 T Liu (2037_CR18) 2023; 45 S Sriramulu (2037_CR22) 2024; 24 M Li (2037_CR32) 2022; 36 S Wahab (2037_CR3) 2021; 910 M PodgOrska (2037_CR20) 2021; 41 MC Lu (2037_CR26) 2018; 33 D Huang (2037_CR9) 2016; 137 S Dogra (2037_CR36) 2021; 19 CF Le (2037_CR6) 2017; 44 A Dey (2037_CR24) 2023; 22 LW Hii (2037_CR11) 2019; 19 P Ravindranathan (2037_CR33) 2018; 8 X Wang (2037_CR15) 2023; 13 Y Feng (2037_CR31) 2024; 129 N Pavlaki (2037_CR17) 2018; 5 YC He (2037_CR5) 2023; 29 C Chaves-Almagro (2037_CR38) 2022; 23 Q Tian (2037_CR39) 2021; 53 RFW Franssen (2037_CR4) 2021; 45 Y Chen (2037_CR35) 2021; 104 LK Boopathy (2037_CR2) 2024; 38 CM Lin (2037_CR8) 2021; 2021 YK Yong (2037_CR25) 2013; 2013 L Qiao (2037_CR16) 2024; 22 G Khalili-Tanha (2037_CR29) 2023; 17 |
References_xml | – volume: 8 start-page: 13869 issue: 1 year: 2018 ident: 2037_CR33 publication-title: Sci Rep doi: 10.1038/s41598-018-32267-8 – volume: 53 start-page: 1538 issue: 11 year: 2021 ident: 2037_CR39 publication-title: Acta Biochim Biophys Sin doi: 10.1093/abbs/gmab134 – volume: 22 start-page: 205 issue: 1 year: 2024 ident: 2037_CR16 publication-title: J Nanobiotechnol doi: 10.1186/s12951-024-02480-x – volume: 17 start-page: 1378 issue: 6 year: 2019 ident: 2037_CR37 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-18-0989 – volume: 33 start-page: 1229 issue: 12 year: 2018 ident: 2037_CR26 publication-title: Environ Toxicol doi: 10.1002/tox.22629 – volume: 19 start-page: 1534 issue: 9 year: 2021 ident: 2037_CR36 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-20-0991 – volume: 17 start-page: 1469 issue: 4 year: 2023 ident: 2037_CR29 publication-title: J Cell Commun Signal doi: 10.1007/s12079-023-00779-2 – volume: 45 start-page: 2924 issue: 9 year: 2021 ident: 2037_CR4 publication-title: World J Surg doi: 10.1007/s00268-021-06188-z – volume: 44 start-page: 203 year: 2017 ident: 2037_CR6 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2017.01.013 – volume: 10 issue: 5 year: 2024 ident: 2037_CR13 publication-title: Heliyon – volume: 29 start-page: 670 issue: 4 year: 2023 ident: 2037_CR5 publication-title: World J Gastroenterol doi: 10.3748/wjg.v29.i4.670 – volume: 29 start-page: 28 issue: 1–2 year: 2022 ident: 2037_CR30 publication-title: Gene Ther doi: 10.1038/s41434-020-0167-3 – volume: 13 issue: 4 year: 2024 ident: 2037_CR14 publication-title: Adv Healthc Mater – volume: 216 issue: 12 year: 2020 ident: 2037_CR23 publication-title: Pathol Res Pract doi: 10.1016/j.prp.2020.153247 – volume: 86 start-page: 400 issue: Pt 3 year: 2022 ident: 2037_CR1 publication-title: Semin Cancer Biol – volume: 45 start-page: 8502 issue: 10 year: 2023 ident: 2037_CR18 publication-title: Curr Issues Mol Biol doi: 10.3390/cimb45100536 – volume: 22 start-page: 153303382311784 year: 2023 ident: 2037_CR24 publication-title: Technol Cancer Res Treat – year: 2024 ident: 2037_CR34 publication-title: Naunyn Schmiedebergs Arch Pharmacol doi: 10.1007/s00210-023-02928-1 – volume: 41 start-page: 151 issue: 1 year: 2021 ident: 2037_CR20 publication-title: Anticancer Res doi: 10.21873/anticanres.14760 – volume: 5 start-page: 4 issue: 1 year: 2018 ident: 2037_CR17 publication-title: J Cardiovasc Dev Dis – volume: 137 start-page: 701 year: 2016 ident: 2037_CR9 publication-title: Carbohydr Polym doi: 10.1016/j.carbpol.2015.10.102 – volume: 13 year: 2023 ident: 2037_CR15 publication-title: Front Oncol – volume: 25 start-page: 1676 issue: 5 year: 2019 ident: 2037_CR19 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-0815 – volume: 24 start-page: 307 issue: 4 year: 2024 ident: 2037_CR22 publication-title: Curr Gene Ther doi: 10.2174/0115665232273077240104045022 – volume: 24 start-page: 10789 issue: 13 year: 2023 ident: 2037_CR7 publication-title: Int J Mol Sci doi: 10.3390/ijms241310789 – volume: 2021 start-page: 5560502 year: 2021 ident: 2037_CR8 publication-title: Evid Based Complement Alternat Med – volume: 23 start-page: 10600 issue: 18 year: 2022 ident: 2037_CR38 publication-title: Int J Mol Sci doi: 10.3390/ijms231810600 – volume: 910 year: 2021 ident: 2037_CR3 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2021.174464 – volume: 35 start-page: 21 issue: 1 year: 2020 ident: 2037_CR28 publication-title: J Biomed Res doi: 10.7555/JBR.34.20200021 – volume: 19 start-page: 257 issue: 1 year: 2019 ident: 2037_CR11 publication-title: BMC Complement Altern Med doi: 10.1186/s12906-019-2663-9 – volume: 29 start-page: 81685 issue: 54 year: 2022 ident: 2037_CR27 publication-title: Environ Sci Pollut Res Int doi: 10.1007/s11356-022-20858-y – volume: 55 start-page: 1093 issue: 1 year: 2017 ident: 2037_CR40 publication-title: Pharm Biol doi: 10.1080/13880209.2017.1288749 – volume: 36 start-page: 3540 issue: 9 year: 2022 ident: 2037_CR32 publication-title: Phytother Res doi: 10.1002/ptr.7521 – volume: 74 start-page: 2622 issue: 7 year: 2022 ident: 2037_CR21 publication-title: Nutr Cancer doi: 10.1080/01635581.2021.2014901 – volume: 15 start-page: 1290592 year: 2024 ident: 2037_CR12 publication-title: Front Pharmacol doi: 10.3389/fphar.2024.1290592 – volume: 16 issue: 8 year: 2021 ident: 2037_CR10 publication-title: PLoS ONE doi: 10.1371/journal.pone.0256012 – volume: 129 year: 2024 ident: 2037_CR31 publication-title: J Nutr Biochem doi: 10.1016/j.jnutbio.2024.109623 – volume: 38 issue: 1 year: 2024 ident: 2037_CR2 publication-title: J Biochem Mol Toxicol doi: 10.1002/jbt.23525 – volume: 2013 year: 2013 ident: 2037_CR25 publication-title: Evid Based Complement Alternat Med – volume: 104 start-page: 368504211011341 issue: 2 year: 2021 ident: 2037_CR35 publication-title: Sci Prog doi: 10.1177/00368504211011341 |
SSID | ssj0002513305 |
Score | 2.299654 |
Snippet | Background
Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and
Clinacanthus nutans... Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.)... BackgroundColon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans... CN exerts anti-tumor effect in colon cancer. CN delays tumorigenesis through suppressing PDE3B. PDE3B silencing enhances cuproptosis in CN-treated cells. CN... Abstract Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1521 |
SubjectTerms | Apelin pathway Cancer Research Cell death Clinacanthus nutans (Burm.f.) Lindau Colon cancer Colorectal cancer Copper Cuproptosis Gas flow Internal Medicine Medicine Medicine & Public Health Molecular Medicine Oncology PDE3B Proteins Radiotherapy Software Surgical Oncology Tumors |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4t1AqYzEAQQuSezE9gl1oVWFVMSBSnuLxk7MRmqTZbPRqj-Df4zHye5qy-Ma-zDxzNifPTPfEPJaSWMNeP-WsTNMuEwwpQywJAOZcgO5cVjgfP41P7sQX6bZdHxw68a0yvWeGDbqsrX4Rv6B-7MFg1Kx-Dj_ybBrFEZXxxYat8kdpC7DlC45lZs3lhSbl8TZWCszVMyluUwZ9nDFEJxkq53zKND2_w1r_pkyeSNuGo6j0wfk_ogj6fGg-IfkVtU8InfPx0j5Y_ILQ7OA6zbrO9r0HgN29M2kX1wduaO3NFzFe-rADizdVUdt7-WZL9uu7ig0JYWr6hLr98OY3yIbatFCFjSkdA10HtRc07qZ1abG7Gn67fMJn7BQjOKBLD2eY7E7xabHK7h-Qi5OT75_OmNj-wVm_aVvxfzGp0soPWL0IAVJZFyWgHEixrZViBtjlyurtctLHXOreQVapYI7XTkJTvKnZK9pm2qfUGkzraVOVAVGeEgCJsldDMpajzYyEBF5t1ZCMR9YNootnzKqrPAqK4LKilVEJqinzUxkyA4f2sWPYnS4QoFUFrxMsb_DJkmpM5eLHJsHJLHjtozIwVrLxei2XbE1soi82gx7h8MoCjRV2w9zhAe9gkfk2WAUG0kwKOoHVUTUjrnsiLo70tSzQOrtEQTXiucReb-2rK1c_16L5___jRfkXhqMXbEkOSB7y0VfvfQoamkOg6v8BnxjHLE priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELWgSIgL4pvQgozEAQQucew49rG7tKqQijhQqbfIdmJtJJpdbTZa9WfwjzvjZLfaUg5cY0caZWbs5zzPG0I-6MJ5ZyG_izQ4JkMumdbOMp7bIhPOKhewwPnshzo9l98v8otRJgdrYW7x9187nqkiY9h0FTmzgq3vkwc5FwojeKqm2_8pGTYqSfOxLubuV3f2nijRfxeu_Pt65C2ONG49J0_I4xEz0qPByU_Jvbp9Rh6ejaz4c_IHaViL32jWd7TtAe919OOkX14ehsNPNB67exqsHxS56476HuxZrOZd01HbVtRe1r-xVj-OwXLYUo_RsKTx-tYg3UHdFW3aWeMavClNf347FhMWC08AtNKjBRa2U2xwvLZXL8j5yfGv6SkbWy0wDwe8NYNFzlS2AnQIgAQFY0LOrQsyxRZViBHToLQ3JqjKpMIbUVujMymCqUNhQyFekr123tavCS18bkxhuK6tkwA_rOMqpFZ7D8gitzIhnzdOKBeDokZ5o52MLivBZWV0WblOyAT9tJ2JatjxAQRJOSZXqW2hvQWbUjivcl6ZPCipsFEAT4PwVUIONl4uxxTtSgFgBVnOFCx6vx2G5ELGxLb1vB_mSAC4UiTk1RAUW0uQAIVBnRC9Ey47pu6OtM0sCngDWhBGC5WQL5vIurHr39_izf9N3yePshj8mnF-QPZWy75-Cwhq5d7F1LkGXj8V_Q priority: 102 providerName: Springer Nature |
Title | Clinacanthus nutans (Burm.f.) Lindau facilitates cuproptosis and ameliorates colon cancer progression by inhibiting PDE3B-mediated Apelin pathway |
URI | https://link.springer.com/article/10.1007/s12672-025-02037-w https://www.ncbi.nlm.nih.gov/pubmed/40788438 https://www.proquest.com/docview/3238529504 https://www.proquest.com/docview/3238432643 https://pubmed.ncbi.nlm.nih.gov/PMC12339836 https://doaj.org/article/8a78ca3ea018411d95f646848110f3cd |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9tAEF7aFEovpe-qTc0WemhplUja1T6OsesQCgmhNOCb2F1psaGRjWVh8jPyjzOzkp24D3rpUVodhnnsfqPZ-YaQD0paZw3Et0y8jbnPeayUNXGaG5kxa4T12OB8eiZOLvi3ST65M-oL74R19MCd4g6VkcoZVpkEcpE0LXXuBRdIAp8mnrkSd1848-4kU7gHZzi2JMn7LpmuVy4TMotxeisW32S83jmJAmH_n1Dm75clf6mYhoPo-Al53CNIetRJ_pTcq-pn5OFpXyN_Tq6xKGtQY9O2oXUL6K-hH4ft8vLAH3yiIQlvqTeu4-euGupakGexmjezhpq6pOay-omd-2ENNseaOvSNJQ2XuToiD2qv6KyezuwM703T869jNoxDGwpAWHq0wDZ3iuOO1-bqBbk4Hv8YncT94IXYQbq3jmHL06UpASsCPEH6GJ-nxnqe4MAqRIyJF8pp7UWpE-Y0WEerjDOvKy-Nl-wl2avndfWaUOlyraVOVWUsBzBibCp8YpRzgDNywyPyeWOEYtHxaxS3TMposgJMVgSTFeuIDNFO2y-RGzu8AI8peo8p_uUxEdnfWLnoA7YpGEAXrHkmINH77TKEGtZPTF3N2-4bDnCXs4i86pxiKwmWQ2FRRUTtuMuOqLsr9Wwa6LwBOzCtmIjIl41n3cr1d128-R-6eEseZSEkVJym-2RvtWyrd4CyVnZA7suJHJAHw_HZ-Xd4GonRIATZIPwSuwEIiCj2 |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2VVAJeEHcMBRYJJBB1sb1re_cBoYamSmkTVaiV-mZ2114SiTohjhXlM_gRvpEZXxKF21tfs1Y0yZnZPePZmUPISxFroxXEd-xZ7XIbclcIrVw_VHHAtIq0xQbnwTDqn_NPF-HFFvnZ9sLgtcp2T6w26nRi8B35OwZnCxalPP5h-t1F1SisrrYSGrVbHGfLBaRsxfujA8D3VRAc9s4-9t1GVcA1kMssXIhnmaoUiBCcvTgbxYa-0pZ7qMaEdMizkTBS2iiVHjOSZUqKgDMrMxsrGzP43mtkmzNIZTpku9sbnn5evdUJUC7FC5vunLpHL4jiwEXVWCz6xe5i4wSshAL-xm7_vKT5W6W2OgAPb5NbDXOl-7Wr3SFbWX6XXB80tfl75AcWgxUiNSoLmpfAOgv6ulvOLvfs3htaJf8ltcrUc8GzgpoS7JnOJ8W4oCpPqbrMvuHEgGoNNuWcGvTJGa0ukdUDRKhe0nE-Gusx3tempwc91nWr9hegznR_iu31FGWWF2p5n5xfCTQPSCef5NkjQmMTShlLX2RKcyBBSvuR9ZQwBvhNqLhD3rYgJNN6rkeynuCMkCUAWVJBliwc0kWcVk_iTO7qg8nsa9KEeCJULIwCmzzImn0_laGNeIRyBb5nmUkdstOinDQbRZGs3dohL1bLEOJYt1F5NinrZzjQbM4c8rB2ipUlWIaFReEQseEuG6ZuruTjUTVGHDgLk4JFDtltPWtt17__i8f__xnPyY3-2eAkOTkaHj8hN4PK8YXr-zukM5-V2VPgcHP9rAkcSr5cdaz-AhDLWmA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkCZeEHcCA4wEEgiyJXES2w8IrXTVxti0Byb1LdhOTCuxtDSNqv4M_g6_jnOcpFW5ve01tqKTfOfYn31uhLwQXButwL55YLUf2yT2hdDKDxPFI6ZVqi0mOJ-epUcX8cdhMtwiP7tcGAyr7NZEt1DnE4N35PsM9hZ0SgXxvm3DIs77g_fT7z52kEJPa9dOo1GRk2K5gONb9e64D1i_jKLB4ecPR37bYcA3cK5Z-GDbMlc5kCLYh7FOik1CpW0cYGcmpEaBTYWR0qa5DJiRrFBSRDGzsrBcWc7gvdfIdc6SEG2MD_nqfifCxilB0ubpNNl6UcojH_vHovuP-4uNvdC1DPgbz_0zXPM3n63bCge3yM2Ww9KDRuluk62ivEN2Tlsv_V3yA93CCjEb1RUta-CfFX3Vq2eXe3bvNXXXADW1yjQVwouKmhrkmc4n1biiqsypuiy-Ye0ANwbLc0kNaueMunCyppQI1Us6LkdjPcbIbXreP2Q93yXCAImmB1NMtKfYcHmhlvfIxZUAc59sl5OyeEgoN4mUXIaiUDoGOqR0mNpACWOA6SQq9sibDoRs2lT4yNa1nBGyDCDLHGTZwiM9xGk1E6tzuweT2desNfZMKC6MApkCOD-HYS4Tm8YpNi4IA8tM7pHdDuWsXTKqbK3gHnm-GgZjRw-OKotJ3cyJgXDHzCMPGqVYSYIOWRgUHhEb6rIh6uZIOR65guLAXpgULPXI206z1nL9-188-v9nPCM7YKHZp-Ozk8fkRuT0XvhhuEu257O6eAJkbq6fOquh5MtVm-kvTGVdMA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinacanthus+nutans+%28Burm.f.%29+Lindau+facilitates+cuproptosis+and+ameliorates+colon+cancer+progression+by+inhibiting+PDE3B-mediated+Apelin+pathway&rft.jtitle=Discover.+Oncology&rft.au=Gaoyun+Zhou&rft.au=Xueying+Lin&rft.au=Zhiheng+Lai&rft.au=Dewen+Su&rft.date=2025-08-11&rft.pub=Springer&rft.eissn=2730-6011&rft.volume=16&rft.issue=1&rft.spage=1&rft.epage=15&rft_id=info:doi/10.1007%2Fs12672-025-02037-w&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_8a78ca3ea018411d95f646848110f3cd |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2730-6011&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2730-6011&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2730-6011&client=summon |